Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases
worldwide and is often associated with aspects of metabolic syndrome. Despite its …
worldwide and is often associated with aspects of metabolic syndrome. Despite its …
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is estimated to afflict approximately 1 billion
individuals worldwide. In a subset of NAFLD patients, who have the progressive form of …
individuals worldwide. In a subset of NAFLD patients, who have the progressive form of …
Metabolic liver disease in diabetes–from mechanisms to clinical trials
Non-alcoholic fatty liver disease (NAFLD) comprises fatty liver (steatosis), non-alcoholic
steatohepatitis (NASH) and fibrosis/cirrhosis and may lead to end-stage liver failure or …
steatohepatitis (NASH) and fibrosis/cirrhosis and may lead to end-stage liver failure or …
Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes
F Bril, MJ McPhaul, MP Caulfield, VC Clark… - Diabetes …, 2020 - Am Diabetes Assoc
OBJECTIVE The 2019 Standards of Medical Care in Diabetes suggested that patients with
nonalcoholic fatty liver disease (NAFLD) should be evaluated for liver fibrosis. However, the …
nonalcoholic fatty liver disease (NAFLD) should be evaluated for liver fibrosis. However, the …
Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the US
OBJECTIVE Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty
liver disease (NAFLD) and is strongly associated with type 2 diabetes mellitus (T2DM) …
liver disease (NAFLD) and is strongly associated with type 2 diabetes mellitus (T2DM) …
The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is a multifaceted metabolic disorder, whose
spectrum covers clinical, histological and pathophysiological developments ranging from …
spectrum covers clinical, histological and pathophysiological developments ranging from …
Diagnostic modalities of non-alcoholic fatty liver disease: from biochemical biomarkers to multi-omics non-invasive approaches
E Martinou, M Pericleous, I Stefanova, V Kaur… - Diagnostics, 2022 - mdpi.com
Non-Alcoholic Fatty Liver Disease (NAFLD) is currently the most common cause of chronic
liver disease worldwide, and its prevalence is increasing globally. NAFLD is a multifaceted …
liver disease worldwide, and its prevalence is increasing globally. NAFLD is a multifaceted …
[HTML][HTML] Recent advances in nonalcoholic fatty liver disease metabolomics
HY Kim - Clinical and molecular hepatology, 2021 - ncbi.nlm.nih.gov
The clinical phenotypes of nonalcoholic fatty liver disease (NAFLD) encompass from simple
steatosis to nonalcoholic steatohepatitis (NASH) with varying degrees of fibrosis or cirrhosis …
steatosis to nonalcoholic steatohepatitis (NASH) with varying degrees of fibrosis or cirrhosis …
Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis
Abstract Introduction Non-Alcoholic Fatty Liver Disease encompasses a spectrum of
diseases ranging from simple steatosis to steatohepatitis (or NASH), up to cirrhosis and …
diseases ranging from simple steatosis to steatohepatitis (or NASH), up to cirrhosis and …
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus
F Bril, MJ McPhaul, MP Caulfield… - Journal of …, 2019 - journals.sagepub.com
Fibromax is a diagnostic tool composed of the combination of 4 non-invasive biomarker
panels for the diagnosis of steatosis (SteatoTest), necrosis and inflammation (ActiTest and …
panels for the diagnosis of steatosis (SteatoTest), necrosis and inflammation (ActiTest and …